NCT06856993 Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
| NCT ID | NCT06856993 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Condition | Sudden Cardiac Death |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-12-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2021-12-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute coronary syndrome (ACS) is one of the main causes of death. Worldwide, tens of millions of patients are hospitalized for coronary heart disease and ACS every year. ACS may show acute myocardial infarction, unstable angina pectoris, and even induce early arrhythmia, leading to sudden death. Sudden cardiac death (SCD) has a strong correlation with ACS. Data from clinical and autopsy studies and death certificates show that 62-85% of patients with out of hospital SCD have a history of ACS, 10% have other cardiac structural abnormalities, and 5% have no cardiac structural abnormalities. An SCD surveillance study from Ireland concluded that most cases occurred in families, and the successful recovery of SCD was mainly related to ventricular fibrillation with arrhythmia. At present, there are few reports on the clinical and prognosis of ACS in China, and there is no guideline or consensus on the prevention and treatment of ACS patients. Known domestic research results show that the proportion of male, overweight / obese, smokers in young ACS patients is higher than that in the elderly group, while the proportion of patients with hypertension, diabetes and cerebrovascular diseases is less than that of the elderly group. The levels of TC, TG, LDL-C and UA and the proportion of low HDL-C in young ACS patients were higher than those in elderly patients; The diagnosis of STEMI was the highest in the young ACS group, while the diagnosis of unstable angina pectoris was the most common in the elderly ACS group. The clinical manifestations of ACS vary greatly. 3% \~ 5% of patients who exclude ACS only through myocardial markers, clinical blood transfusion and ECG still have myocardial infarction (MI). For the emergency department, early prediction of the risk of SCD in ACS patients and timely and accurate screening of high-risk patients are very important.
Eligibility Criteria
Inclusion Criteria: * The death event happens suddenly. * Age ≥ 18 years * The patient had obvious clinical symptoms 24 hours before treatment * Life expectancy exceeds 3 days * Proxy of patients signs the informed consent form * Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016 Exclusion Criteria: * Death caused by accident, such as trauma, poisoning, etc. * Death from accidental or intentional overdose * Death from asphyxia * Death is caused by chronic disease or terminal illness * The patient died naturally * Has participated in other clinical studies * Immediate family members give up continuing treatment
Frequently Asked Questions
Who can join the NCT06856993 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sudden Cardiac Death. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06856993 currently recruiting?
Yes, NCT06856993 is actively recruiting participants. Visit ClinicalTrials.gov or contact The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School to inquire about joining.
Where is the NCT06856993 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06856993 clinical trial?
NCT06856993 is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. The trial plans to enroll 300 participants.